Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $21.92, for a total value of $4,384,000.00. Following the completion of the sale, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at $36,268,766.24. This represents a 10.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Eric Venker also recently made the following trade(s):

• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total value of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.45, for a total value of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.85, for a total value of $4,170,000.00.
• On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.22, for a total transaction of $4,044,000.00.
• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The stock was sold at an average price of $17.06, for a total transaction of $2,020,211.08.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The stock was sold at an average price of $17.05, for a total transaction of $5,426,708.10.

Roivant Sciences Stock Up 1.6%

NASDAQ ROIV opened at $23.81 on Thursday. The firm has a market cap of $16.56 billion, a P/E ratio of -42.52 and a beta of 1.22. The company’s 50 day moving average is $21.40 and its 200-day moving average is $16.46. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $23.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ROIV. Goldman Sachs Group Inc. raised its stake in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares during the last quarter. Inspire Investing LLC purchased a new stake in shares of Roivant Sciences during the 1st quarter valued at $303,000. Wedmont Private Capital bought a new stake in shares of Roivant Sciences during the 2nd quarter worth $124,000. Finally, UMB Bank n.a. lifted its holdings in shares of Roivant Sciences by 42.0% during the 2nd quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock worth $66,000 after acquiring an additional 1,740 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised their price target on Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, September 18th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Weiss Ratings upgraded Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Saturday, October 25th. The Goldman Sachs Group raised their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Guggenheim reaffirmed a “buy” rating and set a $28.00 price objective on shares of Roivant Sciences in a research note on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.